Navigation Links
Ultra low-dose estrogen shown safe for post-menopausal women

A study led by researchers at the San Francisco VA Medical Center has shown that extremely low doses of estrogen had no ill effects on the cognitive abilities or general health of older women over the course of two years.

"This is exciting. It shows that women can take estrogen safely," observes lead author Kristine Yaffe, MD, chief of geriatric psychiatry at SFVAMC and associate professor of psychiatry, neurology, and epidemiology at the University of California, San Francisco.

In 2004, study results from the Women's Health Initiative (WHI), a nationwide longitudinal study sponsored by the National Institutes of Health, indicated that estrogen was associated with an increased risk of dementia among women 65 and older, as well as with an increased risk of heart attack and stroke.

"Those results raised a lot of doubts about whether women should be taking estrogen at all," Yaffe notes.

The current study, published in the July 2006 issue of Archives of Neurology, looked specifically at the potential effects of estrogen on cognitive abilities and quality of life. A group of 417 post-menopausal women aged 60 to 80 were randomly assigned to receive a daily .014 milligram dose of either estradiol, a form of estrogen, or a placebo through a skin patch for two years. The women were given a battery of standardized cognitive tests and a test of health-related quality of life at the beginning of the study, after one year, and after two years.

At the end of the study, there was no difference between the two groups in either cognitive abilities or health-related quality of life.

"The results are very reassuring, because it suggests that women can use this patch without harm for two years," says Yaffe. "It would benefit their bones and might have a beneficial effect in terms of hot flashes."

A related study of the same group of women showed a significant increase in bone density, without adverse health effects, in th e women who took estradiol compared to the women who took placebo. The current study was a pre-planned secondary investigation.

Yaffe speculates that the differences in health and cognition outcomes between these two studies and the WHI studies could be related to three factors: dose, type of estrogen, and means of delivery.

The women in the WHI studies received .625 milligrams per day of conjugated estrogen ?a mixture of estrogen from several different sources ?in pill form. In contrast, the women studied by Yaffe and her associates received a daily dose of estradiol ?pure human estrogen ?that was over 44 times smaller and delivered through a skin patch.

"The different between a patch and a pill is significant because medications taken in pill form are processed through the liver before they reach the bloodstream," explains Yaffe. "It's thought that estrogen in pill form might stimulate the liver to produce substances that can lead to clotting or other adverse side effects. With a patch, you bypass the liver and go straight to the blood."

Yaffe notes that since the WHI results were announced in 2004, "the field of estrogen research has been stymied. Hopefully, this study will start to turn the tide."


'"/>

Source:University of California - San Francisco


Related biology news :

1. Ultrasounds show mothers drinking shrinks fetal brain
2. Ultrasound may help regrow teeth
3. Ultrathin films deliver DNA as possible gene therapy tool
4. Ultrasound upgrade produces images that work like 3-D movies
5. Harmful chemicals may reprogram gene response to estrogen
6. Compounds in plastic packaging act as environmental estrogens altering breast genes
7. Tamoxifen-like drug suggests new ways to selectively block estrogen
8. Researchers uncover mechanisms of estrogen in promoting cell death in breast cancer
9. High estrogen levels associated with dementia in older men
10. New path from estrogen to survival in breast cancer cells described
11. Changing length of days reverses how estrogen affects aggressiveness in mice
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand ... Excellence in Volunteer Experience from US2020. , US2020’s mission is to change the ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
Breaking Biology Technology: